Eupraxia Pharmaceuticals, Inc. EPRX 深 滬
等待開盤 09-08 09:30:00 美东时间
8.40
+0.900
+12.00%
華盛通- 最 高8.40
- 今 開7.45
- 成交量 352.09万股
- 最 低 7.39
- 昨 收 7.50
- 總市值 5.55亿
- 52周最高 9.32
- 市盈率 靜 --
- 換手率 5.33%
- 52周最低 5.16
- 委 比 22.63%
- 總股本 6607.34万
- 歷史最高 9.32
- 量 比 9.52
- 振 幅 13.47%
- 歷史最低 2.20
- 每 手 1
- 風險率 0.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | Belite Bio飙升13.2%，获大行看高至303美元，潜在升幅约77%；存储、光通信板块逆势狂涨！Aehr Test Systems劲升13%，闪迪升近12%
Belite Bio飙升13.2%，获大行看高至303美元，潜在升幅约77%；存储、光通信板块逆势狂涨！Aehr Test Systems劲升13%，闪迪升近12%>>
09-05 06:25
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 250 points on Wednesday. Shares of Sirius XM Holdings Inc (NASDAQ:SIRI) rose sharply during Wednesday’s session after Deutsche Bank upgraded the stock from Hold to Buy and raised its price target from $31 to $45. Sirius XM share...
09-02 22:26
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
Eupraxia Pharmaceuticals Inc. announced positive results from the RESOLVE study, showing EP-104GI significantly reduces symptoms of odynophagia (pain swallowing) and dysphagia (difficulty swallowing) in EoE patients. Moderate to severe odynophagia dropped from 62% at baseline to 25% at 24-52 weeks, with no severe cases reported post-treatment. Similarly, moderate to severe dysphagia decreased from 77% to 25%. EP-104GI demonstrated good tolerabili...
08-13 12:00
Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 11.54 percent increase over losses of $(0.26) per share from the same period last year.
08-12 05:32
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Eupraxia Pharmaceuticals Inc. announced its Q2 2026 financial results, reporting a net loss of $14.5 million, up from $8.7 million in Q2 2025, due to increased R&D and general expenses. The company highlighted positive data from its EP-104GI Phase 1b/2a trial in Eosinophilic Esophagitis (EoE), showing improvement in fibrosis and inflammation. Recent operational highlights include leadership appointments and the expansion of its EP-104GI target in...
08-11 21:21
美股大行评级 | 潜在涨幅90.66%！Tango Therapeutics获杰富瑞升目标价至60美元，上调至"买入"评级
今日重点评级关注：杰富瑞：上调Tango Therapeutics评级至"买入"，目标价从27美元升至60美元；Susquehanna：维持安森美半导体"积极"评级，目标价从120美元升至140美元
06-29 15:49
Oppenheimer Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17
Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
06-26 21:12
Why JOYY Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, CODX +22.7%, MDAI +22%. Losers: AKTX -25.2%, RYOJ -18.6%, DEVS -18.6%, AKAN -17%, ADTX -16.3%, LFS -15.6%
05-26 18:00
美股大行评级 | 英伟达绩后获11家大行集体上调目标价；劳氏、ELF、Intuit、VF等惨遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx药业"超配"评级，目标价从84美元升至96美元；Ascendiant Capital：维持Liqtech国际"买入"评级，目标价从4.3美元升至4.4美元
05-22 10:18
Stifel Initiates Coverage On Eupraxia Pharmaceuticals with Buy Rating, Announces Price Target of $25
Stifel analyst Annabel Samimy initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy rating and announces Price Target of $25.
05-21 18:06
